| Attributes | Values |
|---|
| rdf:type
| |
| description
| - videnskabelig artikel (da)
- article científic (ca)
- articolo scientifico (it)
- artigo científico (pt)
- bilimsel makale (tr)
- vedecký článok (sk)
- vetenskaplig artikel (sv)
- vědecký článek (cs)
- wetenschappelijk artikel (nl)
- wissenschaftlicher Artikel (de)
- научни чланак (sr)
- article scientifique (fr)
- artículu científicu espublizáu en 2014 (ast)
- наукова стаття, опублікована в лютому 2014 (uk)
- scientific article published on 18 February 2014 (en)
- مقالة علمية نشرت في 18 فبراير 2014 (ar)
|
| publication date
| |
| publication date
| |
| language of work or name
| |
| language of work or name
| |
| cites work
| |
| cites work
| - Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes
- Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis
- 10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America
- Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects
- Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece
- Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City
- Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection
- ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates
- Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11
- Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug?
- Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates
- The most frequent aminoglycoside resistance mechanisms--changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups.
- Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
- 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides
- Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009.
- Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009
- Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.
- Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes.
- Synthesis and spectrum of the neoglycoside ACHN-490
- Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin
- Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City
- Aminoglycoside therapy in infectious diseases
- Activity of ACHN-490 against meticillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitals
|
| author name string
| |
| author name string
| - G G Zhanel
- D J Hoban
- J A Karlowsky
- M Baxter
- H Adam
- A Walkty
- A Denisuik
|
| rdfs:label
| - In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. (en)
- In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. (nl)
- In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. (ast)
|
| skos:prefLabel
| - In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. (en)
- In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. (nl)
- In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. (ast)
|
| name
| - In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. (en)
- In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. (nl)
- In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. (ast)
|
| author
| |
| author
| |
| title
| |
| title
| - In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012 (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| main subject
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)